Lipocine Inc. (LPCN)
NASDAQ: LPCN · Real-Time Price · USD
7.30
-0.37 (-4.82%)
Mar 18, 2026, 4:00 PM EDT - Market closed
Lipocine Revenue
In the year 2025, Lipocine had annual revenue of $1.98M, down -82.35%. Lipocine had revenue of $1.15M in the quarter ending December 31, 2025, a decrease of -67.19%.
Revenue (ttm)
$1.98M
Revenue Growth
-82.35%
P/S Ratio
26.96
Revenue / Employee
$123,542
Employees
16
Market Cap
53.29M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.98M | -9.22M | -82.35% |
| Dec 31, 2024 | 11.20M | 8.13M | 264.67% |
| Dec 31, 2023 | 3.07M | 2.57M | 514.16% |
| Dec 31, 2022 | 500.00K | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | 164.99K | -263.04K | -61.45% |
| Dec 31, 2018 | 428.03K | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | 7.71M | - | - |
| Dec 31, 2011 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ImmuCell | 27.64M |
| Metagenomi Therapeutics | 25.21M |
| Radiopharm Theranostics | 10.86M |
| Immutep | 5.28M |
| Mereo BioPharma Group | 500.00K |
LPCN News
- 8 days ago - Lipocine Announces Financial Results for the Full Year Ended December 31, 2025 - PRNewsWire
- 4 weeks ago - Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD) - PRNewsWire
- 2 months ago - Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) - PRNewsWire
- 2 months ago - Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) - PRNewsWire
- 3 months ago - Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone - PRNewsWire
- 4 months ago - Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) - PRNewsWire
- 4 months ago - Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025 - PRNewsWire
- 4 months ago - Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek® - PRNewsWire